

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

December 8, 2025

ISSUE No.
1743

IN THIS ISSUE

A Cardiovascular Indication for Oral Semaglutide (*Rybelsus*)p 195

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions, Site Licenses, Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67 (Issue 1743)

December 8, 2025

Take CME Exams

▶ A Cardiovascular Indication for Oral Semaglutide (*Rybelsus*)

The oral glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (*Rybelsus* – Novo Nordisk), which was approved by the FDA in 2019 for treatment of type 2 diabetes in adults, has now also been approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at high risk for these events.¹ The injectable GLP-1 receptor agonists semaglutide (*Ozempic*), dulaglutide (*Trulicity*), and liraglutide (*Victoza*) are also approved for cardiovascular risk reduction in patients with type 2 diabetes (see Table 1).²

CLINICAL STUDIES – FDA approval of oral semaglutide for the new indication was based on the results of a double-blind trial (SOUL) in 9650 patients ≥50 years old with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both. About 87% of patients had cardiovascular disease at enrollment. Patients were randomized to receive oral semaglutide titrated to 14 mg once daily or placebo in addition to standard care (other glucose-lowering and cardiovascular risk-reducing drugs). After a median of 49.5 months, the incidence of MACE (a composite of nonfatal myocardial infarction [MI], nonfatal stroke, or cardiovascular death), the primary endpoint, was statistically significantly lower in the semaglutide arm compared to the placebo arm (12.0% vs 13.8%; HR 0.86, 95% CI 0.77-0.96 [number needed to treat 55.6]). The reduction was primarily driven by a reduction in nonfatal MI (HR 0.74, 95% CI 0.61-0.89). Cardiovascular mortality and adverse kidney outcomes were similar in both groups.³

DOSAGE, ADMINISTRATION, AND COST – *Rybelsus* is available in two formulations (R1 and R2). The R1 formulation, which is available in 3-, 7-, and 14-mg tablets, should be used for the new indication. Slow titration of the dose can reduce GI adverse effects and improve tolerability. The recommended starting dosage is 3 mg once daily for 30 days; the dose should be increased to 7 mg once daily for 60 days

Table 1. FDA-Approved CV and Renal Indications for GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

Dulaglutide (<i>Trulicity</i>)
▶ Reduce risk of MACE in adults with type 2 diabetes and established CVD or multiple CV risk factors
Liraglutide (<i>Victoza</i>)
▶ Reduce risk of MACE in adults with type 2 diabetes and established CVD
Semaglutide, SC (<i>Ozempic</i>)
▶ Reduce risk of MACE in adults with type 2 diabetes and established CVD
▶ Reduce risk of sustained eGFR decline, end-stage kidney disease, and CV death in adults with type 2 diabetes and CKD
Semaglutide, PO (<i>Rybelsus</i>)
▶ Reduce the risk of MACE in adults with type 2 diabetes who are at high risk for these events

CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; MACE = major adverse cardiovascular events

and, if needed for glycemic control, to 14 mg once daily thereafter. All patients in the SOUL trial were titrated to a semaglutide dose of 14 mg. *Rybelsus* should be taken on an empty stomach in the morning with no more than 4 ounces of plain water. The wholesale acquisition cost (WAC) for a 30-day supply of *Rybelsus* is \$997.60.⁴

CONCLUSION – Addition of the oral glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (*Rybelsus*) to standard treatment reduced the risk of a major adverse cardiovascular event (MACE) in adults with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease. *Rybelsus* has not been directly compared with injectable GLP-1 receptor agonists for this indication. ■

Additional Content Available Online

Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
<https://medicalletter.org/TML-article-1742c>

1. Oral semaglutide (*Rybelsus*) for type 2 diabetes. *Med Lett Drugs Ther* 2019; 61:166.
2. Non-insulin drugs for type 2 diabetes. *Med Lett Drugs Ther* 2025 in press.
3. DK McGuire et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. *N Engl J Med* 2025; 392:2001.

4. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. November 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **VICE PRESIDENT, ADMINISTRATION:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Dartmouth Hitchcock Medical Center; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:
The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):
1 year – \$179; \$65 per year for students, interns, residents, and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk subscriptions.

Get Connected: 

Copyright 2025. ISSN 1523-2859

The Medical Letter